EP3819007

AMGEN
Application Number
EP19208417A
Filing Date
Nov 11, 2019
Status
Granted And Under Opposition
Jun 7, 2024
Grant Date
Jul 10, 2024
External Links
Slate, Register

Biblio Summary

The patent EP3819007B1 was granted on Jul 10, 2024 by Amgen The patent is currently Granted And Under Opposition.

The table below shows 2 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

REGENERON PHARMACEUTICALS, INC.Aug 2, 2024 N.A.
STRAWMAN LIMITEDJul 11, 2024 N.A.

The table below shows the patents of Amgen that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP4209499Charged Depth Filtration Of Antigen-Binding ProteinsAug 7, 20241
EP2637670Prevention Of Adverse Effects Caused By Cd3 Specific Binding DomainsMar 13, 20244
EP4058148Dosing Regimen For Anti-Bcma AgentsMar 13, 20244

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.